BR112023004840A2 - Compostos e métodos para tratamento de dor - Google Patents
Compostos e métodos para tratamento de dorInfo
- Publication number
- BR112023004840A2 BR112023004840A2 BR112023004840A BR112023004840A BR112023004840A2 BR 112023004840 A2 BR112023004840 A2 BR 112023004840A2 BR 112023004840 A BR112023004840 A BR 112023004840A BR 112023004840 A BR112023004840 A BR 112023004840A BR 112023004840 A2 BR112023004840 A2 BR 112023004840A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compounds
- antagonist domain
- tnfα
- ngf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084358P | 2020-09-28 | 2020-09-28 | |
| PCT/EP2021/076524 WO2022064043A1 (en) | 2020-09-28 | 2021-09-27 | Compounds and methods for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004840A2 true BR112023004840A2 (pt) | 2023-04-18 |
Family
ID=78085879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004840A BR112023004840A2 (pt) | 2020-09-28 | 2021-09-27 | Compostos e métodos para tratamento de dor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240026036A1 (https=) |
| EP (1) | EP4217388A1 (https=) |
| JP (1) | JP2023543005A (https=) |
| KR (1) | KR20230084199A (https=) |
| CN (1) | CN117279942A (https=) |
| AU (1) | AU2021350424A1 (https=) |
| BR (1) | BR112023004840A2 (https=) |
| CA (1) | CA3195380A1 (https=) |
| IL (1) | IL301548A (https=) |
| TW (1) | TW202228768A (https=) |
| WO (1) | WO2022064043A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| CA2581208A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| EP2298345A3 (en) | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| EP2238154B1 (en) | 2008-01-18 | 2015-09-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| LT3099713T (lt) * | 2014-02-02 | 2020-07-10 | Medimmune Limited | Chimerinis baltymas, sudarytas iš ngf antagonistinio domeno ir tnfa antagonistinio domeno |
| FI3863647T3 (fi) * | 2018-10-10 | 2024-03-01 | Paradigm Biopharmaceuticals Ltd | Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla |
-
2021
- 2021-09-27 KR KR1020237014327A patent/KR20230084199A/ko active Pending
- 2021-09-27 AU AU2021350424A patent/AU2021350424A1/en not_active Abandoned
- 2021-09-27 IL IL301548A patent/IL301548A/en unknown
- 2021-09-27 US US18/246,794 patent/US20240026036A1/en active Pending
- 2021-09-27 CN CN202180065320.3A patent/CN117279942A/zh active Pending
- 2021-09-27 BR BR112023004840A patent/BR112023004840A2/pt unknown
- 2021-09-27 JP JP2023519051A patent/JP2023543005A/ja active Pending
- 2021-09-27 WO PCT/EP2021/076524 patent/WO2022064043A1/en not_active Ceased
- 2021-09-27 CA CA3195380A patent/CA3195380A1/en active Pending
- 2021-09-27 EP EP21789613.3A patent/EP4217388A1/en active Pending
- 2021-09-28 TW TW110136070A patent/TW202228768A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301548A (en) | 2023-05-01 |
| EP4217388A1 (en) | 2023-08-02 |
| CN117279942A (zh) | 2023-12-22 |
| JP2023543005A (ja) | 2023-10-12 |
| WO2022064043A1 (en) | 2022-03-31 |
| AU2021350424A1 (en) | 2023-06-01 |
| KR20230084199A (ko) | 2023-06-12 |
| TW202228768A (zh) | 2022-08-01 |
| CA3195380A1 (en) | 2022-03-31 |
| US20240026036A1 (en) | 2024-01-25 |
| AU2021350424A9 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004474A8 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
| ZA202100718B (en) | Antibody molecules that bind cd137 and ox40 | |
| Teisseyre et al. | Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy | |
| BR112022012437A2 (pt) | Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo | |
| BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos | |
| BRPI0410129B8 (pt) | anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica | |
| BRPI0515404A (pt) | uso de um polipeptìdeo de anticorpo, polipeptìdeo de anticorpo, antagonista de cd40l, composição, formulação farmacêutica de liberação prolongada, e, ligando especìfico duplo | |
| NZ597915A (en) | Combination therapy for treatment of immune disorders | |
| BR112022024084A2 (pt) | Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos | |
| EA200970317A1 (ru) | Комбинированное лечение опухолей, экспрессирующих cd38 | |
| BR112022022418A2 (pt) | Anticorpos de alvejamento de clec12a e uso dos mesmos | |
| Nagasaka et al. | Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/T790M/G796S) in cis | |
| Gerds et al. | PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis | |
| BR112023004840A2 (pt) | Compostos e métodos para tratamento de dor | |
| BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
| BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
| BR112022009147A2 (pt) | Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune | |
| EA201991870A1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 | |
| BR112022009265A2 (pt) | Método de tratamento do câncer e método para aumentar, potencializar ou estimular uma resposta ou função imune | |
| BR112022022900A2 (pt) | Método de tratamento de um câncer | |
| BR112022025801A2 (pt) | Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação | |
| BR112021020612A2 (pt) | Métodos para tratamento de sujeitos com artrite psoriática | |
| BR112022005060A2 (pt) | Uso do anticorpo anti-pcsk9 em método para prevenção ou tratamento de doenças relacionadas ao colesterol |